Clinical trial
A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
NCT01723774 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
- Lead sponsor
- Washington University School of Medicine
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- April 10, 2013
- Completion date
- November 7, 2027
- Enrollment
- 84 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.